Pacer Advisors Inc. Has $2.02 Million Position in Eli Lilly and Co (LLY)

Pacer Advisors Inc. increased its holdings in Eli Lilly and Co (NYSE:LLY) by 10.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,616 shares of the company’s stock after purchasing an additional 2,215 shares during the quarter. Pacer Advisors Inc.’s holdings in Eli Lilly and were worth $2,020,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Thompson Siegel & Walmsley LLC increased its stake in Eli Lilly and by 30.9% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 4,236 shares of the company’s stock worth $362,000 after buying an additional 1,000 shares in the last quarter. Vaughan David Investments Inc. IL increased its stake in Eli Lilly and by 61.2% during the 3rd quarter. Vaughan David Investments Inc. IL now owns 5,995 shares of the company’s stock worth $377,000 after buying an additional 2,277 shares in the last quarter. Banque Pictet & Cie SA increased its stake in Eli Lilly and by 15.5% during the 3rd quarter. Banque Pictet & Cie SA now owns 143,953 shares of the company’s stock worth $12,314,000 after buying an additional 19,293 shares in the last quarter. Spectrum Management Group Inc. purchased a new stake in Eli Lilly and during the 3rd quarter worth approximately $349,000. Finally, Pictet & Cie Europe SA increased its stake in Eli Lilly and by 31.7% during the 3rd quarter. Pictet & Cie Europe SA now owns 69,977 shares of the company’s stock worth $5,986,000 after buying an additional 16,827 shares in the last quarter. 76.30% of the stock is owned by institutional investors.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders sold 651,088 shares of company stock worth $56,439,586 over the last quarter. 0.20% of the stock is currently owned by insiders.

Several research firms have commented on LLY. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, December 12th. Morgan Stanley boosted their price objective on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 21st. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Berenberg Bank restated a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $90.25.

Shares of Eli Lilly and Co (LLY) opened at $85.07 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The stock has a market capitalization of $94,264.75, a P/E ratio of 40.32, a PEG ratio of 1.77 and a beta of 0.35. Eli Lilly and Co has a 52-week low of $72.68 and a 52-week high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period in the prior year, the business earned $0.88 earnings per share. The business’s revenue was up 9.0% compared to the same quarter last year. sell-side analysts predict that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.64%. Eli Lilly and’s dividend payout ratio is currently 98.58%.

ILLEGAL ACTIVITY WARNING: “Pacer Advisors Inc. Has $2.02 Million Position in Eli Lilly and Co (LLY)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/23/pacer-advisors-inc-has-2-02-million-position-in-eli-lilly-and-co-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit